A crosstalk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity

Archive ouverte

Boulch, Morgane | Cazaux, Marine | Loe-Mie, Yann | Thibaut, Ronan | Corre, Béatrice | Lemaître, Fabrice | Grandjean, Capucine | Garcia, Zacarias | Bousso, Philippe

Edité par CCSD ; American Association for the Advancement of Science (AAAS) -

International audience. Chimeric antigen receptor (CAR) T cell therapy relies on the activity of a large pool of tumor-targeting cytotoxic effectors. Whether CAR T cells act autonomously or require interactions with the tumor microenvironment (TME) remains incompletely understood. Here, we report an essential cross-talk between CAR T cell subsets and the TME for tumor control in an immunocompetent mouse B cell lymphoma model of anti-CD19 CAR T cell therapy. Using single-cell RNA sequencing, we revealed substantial modification of the TME during CAR T cell therapy. Interferon-γ (IFN-γ) produced by CAR T cells not only enhanced endogenous T and natural killer cell activity but was also essential for sustaining CAR T cell cytotoxicity, as revealed by intravital imaging. CAR T cell-derived IFN-γ facilitated host interleukin-12 production that supported host immune and CAR T cell responses. Compared with CD8+ CAR T cells, CD4+ CAR T cells were more efficient at host immune activation but less capable of direct tumor killing. In summary, CAR T cells do not act independently in vivo but rely instead on cytokine-mediated cross-talk with the TME for optimal activity. Invigorating CAR T cell interplay with the host represents an attractive strategy to prevent relapses after therapy.

Suggestions

Du même auteur

Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4+ CAR T-cell antitumor activity

Archive ouverte | Boulch, Morgane | CCSD

International audience. Abstract CD4 + T cells and CD4 + chimeric antigen receptor (CAR) T cells display highly variable antitumor activity in preclinical models and in patients; however, the mechanisms dictating ho...

A major role for CD4+ T cells in driving cytokine release syndrome during CAR T cell therapy

Archive ouverte | Boulch, Morgane | CCSD

International audience. Anti-CD19 chimeric antigen receptor (CAR) T cell therapy represents a breakthrough for the treatment of B cell malignancies. Yet, it can lead to severe adverse events, including cytokine rele...

Single-cell imaging of CAR T cell activity in vivo reveals extensive functional and anatomical heterogeneity

Archive ouverte | Cazaux, Marine | CCSD

International audience. CAR T cells represent a potentially curative strategy for B cell malignancies. However, the outcome and dynamics of CAR T cell interactions in distinct anatomical sites are poorly understood....

Chargement des enrichissements...